Adjuvant therapy in Stage i carcinoma of the breast: The influence of multigene analyses and molecular phenotyping

Gordon F. Schwartz, Harry Bartelink, Harold J. Burstein, Blake Cady, Luigi Cataliotti, Ian S. Fentiman, Roland Holland, Kevin S. Hughes, Shahla Masood, Beryl McCormick, Juan A. Palazzo, Peter I. Pressman, Jorge Reis-Filho, Lajos Pusztai, Emiel J.T. Rutgers, Andrew D. Seidman, Lawrence J. Solin, Joseph A. Sparano

Research output: Contribution to journalArticle

8 Scopus citations


A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.

Original languageEnglish (US)
Pages (from-to)303-311
Number of pages9
JournalBreast Journal
Issue number4
Publication statusPublished - Jul 1 2012



  • Her-2-neu
  • Ki-67
  • adjuvant therapy
  • breast carcinoma
  • estrogen receptors
  • gene analysis
  • progesterone receptors

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology

Cite this